Methodology 4 min read
Timing Peptide Doses Around Training: How the Conversation Got Specific
A historical look at how the peptide-protocol conversation moved from "take it daily" to specific timing recommendations around training, sleep, and meal windows, and what the literature actually supports for each compound class.
Last reviewed: May 2026
The early peptide-research conversation, in the 1990s and 2000s, was simple about timing. The dose was the dose. You took it once daily and moved on. The pharmacokinetic conversations that mattered were about absorption and half-life. Timing within the day was a footnote. Most researchers running peptide protocols in that era took their compounds in the morning, simply because morning was when most other supplements were taken.
The conversation has become considerably more specific since then. The shift came from two sources. The first was better understanding of natural endogenous patterns: the slow-wave-sleep GH pulse, the cortisol awakening response, the post-exercise hormonal window. The second was the accumulation of research-protocol experience that made it clear timing actually mattered, and not always in the ways that intuition would predict.
The GH-pulse compounds
The clearest case for timing specificity is the GH-pulse stack: CJC-1295 + Ipamorelin and adjacent compounds. The argument here is grounded in physiology. Endogenous growth hormone release is pulsatile. The largest natural pulses occur during slow-wave sleep, with smaller pulses driven by exercise and certain meal patterns. A GH-secretagogue dose timed to align with these natural windows produces a different downstream effect than the same dose given at a random time of day.
By the late 2000s, research protocols had settled on the pre-bed dose as the highest-priority timing slot. The reasoning: the body is already releasing endogenous GH at that window, so the secretagogue effect compounds with the natural pulse rather than fighting against a low-secretion period. The post-training dose, when used, exploits the second-largest natural pulse window. Our CJC + Ipamorelin piece covers the operational detail.
The empty-stomach rule emerged from the same physiological grounding. Insulin release blunts GH secretion for 1 to 3 hours. A pre-bed dose taken after a carbohydrate-rich meal wastes most of the secretagogue effect. The 90-minutes-after-meal, 30-minutes-before-next-meal rule came out of practical observation alongside the underlying biochemistry.
The recovery peptides
BPC-157 timing is more flexible, but the conversation has still gotten specific in useful ways. The standard early-protocol pattern was once-daily subcutaneous injection at any convenient time. The current research-protocol consensus has moved toward two patterns: once-daily injection near the affected tissue (for localised soft-tissue work) or twice-daily injection split into morning and pre-training doses (for protocols with both systemic and acute-recovery goals).
The proximity-to-injury principle, where injection near the target tissue produces measurably better outcomes than distant injection, came out of the animal-model work. The research-protocol translation to human use has been adopted broadly, though the human-research evidence base is thinner than the animal data.
TB-500 timing leans differently. Because the compound has longer plasma kinetics and works on broader systemic mechanisms, the dose timing within the day matters less. The dose frequency (typically twice weekly rather than daily) matters more. Researchers running BPC + TB-500 stacks generally treat the BPC component with daily timing precision and the TB-500 component with weekly cadence rather than daily timing.
The GLP-class compounds
This is the timing conversation that reached the most precise published evidence first, simply because the GLP-class compounds went through pharma-scale clinical trials. The dose timing for these compounds is once-weekly subcutaneous injection on the same day each week. The published trial protocols established this pattern across SG, MNJ, and RT lines. The 7-day plasma kinetic profile of these compounds means daily dosing is unnecessary and weekly dosing is optimal.
Within the day of injection, timing matters less. Most trial protocols have participants inject in the morning, but the data does not support a clinically meaningful difference between morning, midday, or evening injection. The day-of-week consistency is the meaningful timing constraint.
The cognitive peptides
Selank and Semax are the cleanest case for intra-day timing specificity in the cognitive category. Both compounds are intranasal, with onset in roughly 5 to 15 minutes from administration and effect duration of 4 to 6 hours. Standard protocols run 2 to 3 administrations per day, timed to the windows where the cognitive support is most needed.
The practical pattern that has emerged: a morning dose for the work-day baseline, an early-afternoon dose to bridge the post-lunch dip, and an optional late-afternoon dose for cognitive demands extending into evening. Researchers who run Selank specifically for stress-regulation often shift the timing toward stress-anticipated windows rather than fixed clock times.
The longevity peptides
NAD+, MOTS-c, Epitalon, and the broader longevity-stack compounds tend to have less precise intra-day timing requirements. The mechanisms involved (cellular maintenance, gene expression modulation, cofactor support) operate on timescales that do not benefit from clock-time precision the way GH-pulse compounds do. Most longevity protocols run their compounds at consistent times of day for routine adherence rather than physiological optimisation.
Epitalon courses are an exception within this category. The standard 10-to-20-day course, repeated once or twice per year, is itself a timing specification, even if the within-day timing is flexible.
What the conversation has settled into
Modern research-protocol design treats timing specificity as compound-class-specific. GH-pulse compounds get clock-precise timing aligned to sleep and exercise. Recovery peptides get proximity-to-injury and twice-daily split. GLP-class compounds get day-of-week consistency. Cognitive peptides get task-anticipated within-day pattern. Longevity compounds get routine-adherence rather than physiological-window targeting.
This is more nuanced than the early-2000s “once daily, morning, with food” advice. It is also more grounded in the underlying physiology, which is the right direction for the field.
What pairs with timing-aware protocol design
- The Protocol Builder seeds curated stacks with the standard timing patterns built into the recommendations
- The Dosage Calculator handles the dose-calculation side once the timing pattern is set
- The Ingredient Library per-compound entries document the timing patterns the literature supports